so long 20/21 FY year... onwards and upwards, page-25

Don't preclude the possibility of Thermo Fisher being the Distributor @flick. Otherwise they must be doing something with us.

Below from a recent LBT Linkedin post - certainly a lot of their employees active on the post.

Yes LBT is tiny at the moment, but we've already worked and / or working with some big names: Johns Hopkins, Beckman Coulter, Heath Services Laboratory/ Sonic Healthcare (who have not only purchased 2 instruments but now become a reference site) so Thermo Fisher should be a possibility.

The technology is good (as demonstrated by the 5 x ECCMID posters, Johns Hopkins and other evaluations) and we're starting to see early data of the APAS being able to read culture plates earlier than the human eye (that'd be a game changer). We just need to start seeing the commercialisation come to fruition.

There are several catalysts which will hopefully support this. Lets hope we get the MRSA (FDA approval) and the US Distributor in the next 7 weeks.

Analysis Modules

• MRSA Module (FDA) Q3
• Urine Module (CE Mark) Q4
• VRE Module (CE Mark) Q4
• AMR Module Q1 (2022)

Sales

• 6 x APAS instruments sold

	Sales	Region	Execution
1	1 x St Vincents Hospital	AUD	Sale
2	1 x Labor de Wisplinghoff	EU	Sale
3	1 x Hennepin County Medical	US	Sale
4	1 x Limbach Group	EU	Sale
5	2 x HSL (Sonic Healthcare)	UK	Sale
6
7	Known Pipeline	Region	Execution
8	1 x Royal Adelaide Hospital	AU	Trialled
9	1 x US (West Coast lab)	US	Trialling (now)
10	1 x UK (Beckman Coulter identified)	EU	Trialling (now)
11	1 x France (Beckman Coulter identified)	EU	Trialling (Sep)
12	2 x US (Advent Health Hospitals)	US	Potential
13	"Several" x US (Following workflow assessments)	US	Potential